If Hairgenetix doesn’t deliver results in 4 months, get a full refund in just 3 simple steps.
Trusted by hundreds and rated
With an 'Excellent' rating of 4.6 stars, based on over 1,200 reviews, our customers' trust in Hairgenetix reflects the remarkable results you can achieve with our hair growth products.
Our products are third-party clinically tested
In a 150-day clinical trial involving 30 men and women aged 18–65 with diverse types of hair loss, the Hairgenetix serum achieved a clinically proven 93% reduction in hair shedding.
Can a Copper Peptide Make Hair Follicles Grow? What This 2007 Lab Study Found
Posted by Hyun Keol Pyo, Chong Hyun Won, Kyu Han Kim et al. on March 05, 2026
Key Findings at a Glance
The copper peptide AHK-Cu made human hair follicles grow significantly longer in laboratory conditions (p < 0.001). It boosted the proliferation of dermal papilla cells — the "command centre" that tells hair to grow (p < 0.001). It reduced the cell death enzyme caspase-3 by 42.7% and the self-destruct marker PARP by 77.5% (both p < 0.05). It shifted the Bcl-2/Bax survival balance toward cell protection (p < 0.05). Effects were seen at extremely low concentrations (10-12 to 10-9 M), but higher concentrations actually inhibited growth — demonstrating a precise dose-response relationship. This is the foundational laboratory study that established copper peptides as a viable hair growth ingredient.
Research Evidence Summary
Condition
Hair follicle growth stimulation and dermal papilla cell survival
This article is a plain-language summary of a peer-reviewed scientific study. It is intended to make clinical research more accessible and is not medical advice. Always consult a qualified healthcare professional before starting any new treatment. The original study was conducted independently at Seoul National University and is not affiliated with Hairgenetix.
Reviewed by: Esther Bodde — Cosmetic & Medical Doctor (MD)
Why This Research Matters
If you are experiencing hair loss, you have probably come across copper peptides as a potential treatment. But does the science actually support them? This 2007 study from Seoul National University is the cornerstone of copper peptide hair research — it was the first to demonstrate, using real human hair follicles, that a specific copper peptide called AHK-Cu can directly stimulate hair growth at the cellular level.
Before this study, researchers already knew that copper peptides could stimulate skin fibroblasts (the cells that produce collagen) and boost vascular endothelial growth factor (VEGF) — a molecule that improves blood supply. What they did not know was whether copper peptides could also affect the specialised cells inside hair follicles. This study answered that question with a clear yes — and mapped the specific biological pathways involved.
The team at Seoul National University's Department of Dermatology took a two-pronged approach to test whether the copper peptide AHK-Cu affects hair growth:
1. Testing on real hair follicles (ex vivo organ culture)
They collected hair follicles from the occipital (back) scalp region of 10 healthy volunteers aged 20–35. A total of 240 hair follicles were isolated and placed in controlled laboratory conditions (Williams' E Medium at 37°C). Follicles were treated with AHK-Cu at concentrations ranging from 10-13 M to 10-7 M (covering six orders of magnitude), with 30 follicles per concentration group. After 12 days, the researchers measured how much each follicle had grown compared to vehicle-treated controls.
2. Testing on follicle command cells (in vitro cell culture)
They isolated dermal papilla cells (DPCs) from human hair follicles and grew them in culture dishes. These cells sit at the base of each hair follicle and act as the "command centre" that signals the hair to grow. Using the MTT assay (a standard test for cell viability), they measured whether AHK-Cu made these cells multiply faster. They also ran flow cytometry (Annexin V/PI staining) and western blot analysis to measure specific survival and death markers: Bcl-2, Bax, caspase-3, and PARP.
What Is an Ex Vivo Study?
An ex vivo study tests living tissue that has been taken from the body and maintained in laboratory conditions. Unlike a pure cell culture (where individual cells grow in a dish), ex vivo organ culture preserves the complete tissue structure — in this case, whole hair follicles with all their cell types intact. This is considered more realistic than pure in vitro testing because the natural architecture and cell-to-cell communication is maintained.
Ex vivo studies sit between test-tube experiments and full clinical trials on the evidence scale. They provide strong proof that a compound has a direct biological effect on the target tissue, but they cannot tell us how that compound will behave when applied to human skin (where absorption, distribution, and metabolism add complexity). This is why ex vivo findings need to be confirmed in human trials — which subsequent studies like the 2016 GHK peptide clinical trial and the 2021 copper tripeptide serum trial have done.
AHK-Cu at concentrations between 10-12 and 10-9 M stimulated measurable hair follicle elongation over 12 days. The treated follicles physically grew more than the untreated controls, with the effect reaching high statistical significance. Crucially, this worked at extremely low concentrations — picomolar to nanomolar — suggesting high biological potency.
Higher concentrations inhibited growth — a biphasic response
At 10-8 M, follicle elongation was inhibited by 14.8 ± 1.2% (2.3 ± 0.18 mm). At 10-7 M, inhibition reached 81.5 ± 40.8% (only 0.5 ± 0.25 mm of growth). This biphasic dose-response demonstrates that "more is not better" — there is an optimal concentration window for copper peptide efficacy.
The MTT assay confirmed that DPCs treated with AHK-Cu at 10-12 to 10-9 M proliferated at a significantly higher rate than untreated cells. More dermal papilla cells means a stronger growth signal being sent to the hair follicle. At 10-8 M, no proliferative effect was observed — consistent with the follicle results.
Cell death enzyme caspase-3 reduced by 42.7% (p < 0.05)
After 72 hours of treatment with 10-9 M AHK-Cu, the levels of cleaved caspase-3 — the "executioner" enzyme that carries out programmed cell death — were reduced by 42.7% compared to untreated controls. This is a direct measurement of reduced cell death.
Self-destruct marker PARP reduced by 77.5% (p < 0.05)
PARP cleavage fragments (a downstream marker of caspase-3 activation) were reduced by 77.5% after 72 hours of treatment. This confirms the anti-apoptotic effect through a second, independent measurement. The magnitude of this reduction is particularly striking.
After 24 hours at 10-9 M, the ratio of Bcl-2 (a "stay alive" protein) to Bax (a "self-destruct" protein) shifted significantly in favour of cell survival. Bcl-2 expression increased while Bax expression decreased — both reaching statistical significance (p < 0.05 each).
Anti-apoptotic effects of AHK-Cu on human dermal papilla cells. Data from Pyo et al., Archives of Pharmacal Research (2007). All results statistically significant at p < 0.05.
How AHK-Cu Works: The Biological Mechanisms
This study identified two distinct pathways through which AHK-Cu promotes hair growth:
1. Direct proliferative effect on dermal papilla cells
AHK-Cu stimulated DPCs to multiply, increasing the pool of growth-signalling cells at the base of each follicle. Dermal papilla cells are the "command centre" of hair growth — they secrete growth factors that instruct the surrounding follicular epithelial cells to proliferate and differentiate into hair. More DPCs means a stronger, more sustained growth signal.
2. Anti-apoptotic protection of dermal papilla cells
AHK-Cu protected DPCs from programmed cell death through multiple molecular pathways:
Bcl-2/Bax rebalancing: Bcl-2 (an anti-apoptotic protein dominant during the telogen-to-anagen transition) was upregulated, while Bax (a pro-apoptotic protein) was downregulated. This shifts the cellular "survival vote" toward staying alive.
Caspase-3 suppression: The "executioner" enzyme of apoptosis was reduced by 42.7%, directly blocking the cell death cascade.
PARP cleavage inhibition: PARP, a downstream target of caspase-3, saw its cleavage fragments reduced by 77.5%. This confirms the anti-apoptotic effect is operating through the classical apoptotic pathway.
The broader copper peptide network
The paper also notes that copper peptide complexes (including the related GHK-Cu) are known to increase VEGF (vascular endothelial growth factor) production and decrease TGF-β1 secretion by dermal fibroblasts. VEGF promotes hair growth by improving blood vessel formation around follicles, while androgen-induced TGF-β1 suppresses epithelial cell growth in androgenetic alopecia. This suggests copper peptides may work through at least four mechanisms: DPC proliferation, anti-apoptosis, VEGF stimulation, and TGF-β1 suppression.
Clinical Interpretation
Several aspects of these results deserve expert-level analysis:
The biphasic dose-response is clinically important. Hair follicle growth was stimulated at 10-12 to 10-9 M but inhibited at 10-8 to 10-7 M. This means topical copper peptide formulations need precise concentration targeting. Higher concentrations are not more effective — they can be counterproductive. This is relevant for product formulation and explains why some copper peptide products may work better than others.
The anti-apoptotic effect is more robust than the proliferative effect. While the flow cytometric apoptosis reduction (3.48%) was not statistically significant, the molecular markers (caspase-3 down 42.7%, PARP down 77.5%, Bcl-2/Bax shift) were all highly significant. This suggests AHK-Cu primarily protects existing DPCs from death rather than simply making them multiply faster — an important distinction for treating hair loss where follicle miniaturisation involves progressive cell loss.
The effective concentrations are remarkably low. Picomolar to nanomolar activity suggests high receptor affinity and potent biological signalling, which is encouraging for topical delivery where only a fraction of applied compound reaches the follicle.
The tissue source matters. Follicles came from the occipital (back) scalp — the region least affected by androgenetic alopecia. Effects on frontal or vertex follicles (where hair loss actually occurs) may differ, though subsequent studies have confirmed activity in these regions.
How This Compares to Other Research
This foundational 2007 study has been built upon by a growing body of copper peptide research:
Pickart & Margolina (2018) — In their comprehensive review of GHK-Cu regeneration science, the authors confirmed that copper peptide hair-stimulating effects appeared comparable to 2% minoxidil, with a superior safety profile. They cited Pyo et al. as foundational evidence.
Lee, Kim et al. (2016) — This clinical trial moved from the laboratory to real patients, testing GHK-peptide combined with 5-ALA on human volunteers. They demonstrated a 7.4× increase in hair count — validating in humans what Pyo et al. showed in the lab.
Pamela R.D. (2021) — This placebo-controlled clinical study tested copper tripeptide serum in a double-blind design, providing the gold-standard clinical evidence that followed from this laboratory foundation.
Kuceki, Wambier et al. (2025) — This recent study combined copper peptides with microneedling and demonstrated 26.5% hair regrowth. The microneedling creates micro-channels that deliver copper peptides directly to the dermal papilla — the exact target cells identified in Pyo et al.'s 2007 work.
Minoxidil comparison (Han et al., 2004) — The same research group previously studied minoxidil using the identical DPC model and found similar proliferative and anti-apoptotic mechanisms. This suggests copper peptides and minoxidil may share overlapping pathways, raising the possibility of complementary or additive effects when used together.
Experimental Parameters
Parameter
Detail
Compound tested
AHK-Cu (L-alanyl-L-histidyl-L-lysine-Cu²⁺), 11% stock solution from Procyte Co.
Effective concentration range
10⁻¹² to 10⁻⁹ M (picomolar to nanomolar)
Inhibitory concentration range
10⁻⁸ to 10⁻⁷ M (micromolar — higher doses are counterproductive)
Follicle source
Occipital scalp, 10 healthy volunteers aged 20–35
Follicles analysed
240 total (30 per concentration group)
Culture duration
12 days (ex vivo); 24–72 hours (in vitro DPC assays)
Culture medium
Williams' E Medium + L-glutamine + insulin + hydrocortisone + antibiotics
Cell passage
Fourth-passage DPCs
Key assays
MTT (viability), Annexin V/PI (apoptosis), Western blot (Bcl-2, Bax, caspase-3, PARP)
Statistical method
Student t-test and Wilcoxon rank-sum test; p < 0.05 = significant
Research Limitations
This study has several limitations that are important to understand in context:
Laboratory study, not a clinical trial. While ex vivo organ culture uses real human tissue, it cannot fully replicate conditions on a living scalp — including skin absorption, blood supply, hormonal influences, and the immune system. Laboratory results may not directly translate to real-world topical use.
Occipital follicles only. All hair follicles came from the back of the scalp — the area least affected by androgenetic alopecia. Follicles from the frontal or vertex regions (where pattern baldness occurs) may respond differently to AHK-Cu due to their distinct androgen sensitivity.
Small donor group for ex vivo work. Although 240 follicles were tested, they came from only 3 volunteers for the organ culture component. Individual genetic variation could influence results.
Short culture period. The 12-day ex vivo culture captures only a snapshot of the hair growth cycle. Long-term effects on follicle cycling (anagen, catagen, telogen transitions) were not assessed.
Apoptosis reduction was not statistically significant by flow cytometry. The 3.48% reduction in apoptotic cells did not reach statistical significance, though the molecular markers (caspase-3, PARP, Bcl-2/Bax) were all significant. This discrepancy may reflect the sensitivity difference between the two measurement methods.
Funding disclosure. The study was supported partly by a research agreement with AmorePacific Corporation (a major Korean cosmetics company). While the research was conducted at Seoul National University with IRB approval, commercial funding is a standard disclosure to note.
What This Means For Your Hair
This study demonstrates four things that matter for anyone dealing with hair loss:
Copper peptides directly stimulate hair growth — not just the skin around the hair, but the actual follicle growth machinery. This is the first study to prove it using human tissue.
They protect the cells that control hair growth — in many types of hair loss, dermal papilla cells gradually die off or become inactive. AHK-Cu helps keep them alive and multiplying, with caspase-3 (a key death enzyme) reduced by 42.7% and PARP (a downstream destruction marker) reduced by 77.5%.
They work at very low concentrations — the effective doses were picomolar to nanomolar, suggesting that even modest topical application could deliver meaningful amounts to the follicle. Research like the 2025 Kuceki study shows that combining copper peptides with microneedling further enhances delivery to the target cells.
Concentration matters — higher doses actually inhibited growth, so well-formulated products with precise concentrations are important. More copper peptide is not automatically better.
This is why copper peptides (specifically AHK-Cu and its close relative GHK-Cu) are now considered one of the most promising non-pharmaceutical approaches to hair loss. They address the root cause — follicle miniaturisation and dermal papilla cell death — rather than just masking symptoms.
Key Terms Explained
AHK-Cu (Alanyl-Histidyl-Lysine Copper)
A small chain of three amino acids (alanine, histidine, lysine) bound to a copper ion. It belongs to the copper peptide family and can interact with cells to trigger growth and survival responses. Also known as copper tripeptide-3.
Dermal papilla cells (DPCs)
Specialised fibroblast cells at the base of each hair follicle that act as the "command centre" for hair growth. They secrete growth factors that instruct follicular cells to proliferate and form hair. Their health and number directly determine hair thickness and growth.
Ex vivo
Testing performed on living tissue taken from the body and maintained in laboratory conditions. More realistic than pure cell cultures because the complete tissue architecture is preserved, but less definitive than a human clinical trial.
Apoptosis
Programmed cell death — a normal process where cells intentionally self-destruct. In hair loss, excessive apoptosis in follicle cells leads to thinner, weaker hair and eventually follicle shutdown.
Bcl-2 / Bax ratio
A molecular "survival score." Bcl-2 is an anti-apoptotic protein that protects cells from death; Bax is a pro-apoptotic protein that promotes death. A higher Bcl-2/Bax ratio means cells are more likely to survive. AHK-Cu increased Bcl-2 and decreased Bax.
Caspase-3
The "executioner" enzyme of programmed cell death. When activated (cleaved), it dismantles the cell from inside. AHK-Cu reduced active caspase-3 by 42.7%, directly blocking this cell death pathway.
PARP (Poly ADP-Ribose Polymerase)
A protein involved in DNA repair. When caspase-3 is activated, it cleaves PARP into fragments — a hallmark of apoptosis. AHK-Cu reduced PARP cleavage fragments by 77.5%, confirming reduced cell death.
Follicle miniaturisation
The gradual shrinking of hair follicles that occurs in pattern baldness (androgenetic alopecia). Each growth cycle produces thinner, shorter hairs until the follicle eventually stops producing visible hair altogether. This process involves progressive DPC loss — exactly what AHK-Cu counteracts.
Frequently Asked Questions
Does this study prove copper peptides grow hair in real people?
This study proves that AHK-Cu directly stimulates hair follicle growth and protects the key growth cells at the cellular level, using real human tissue. However, it is a laboratory study, not a clinical trial on living patients. Subsequent human studies — including the 2016 Lee et al. clinical trial showing a 7.4× hair count increase and the 2021 Pamela R.D. placebo-controlled study — confirmed these effects in real-world use.
What is the difference between AHK-Cu and GHK-Cu?
Both are copper peptides with slightly different amino acid chains. AHK-Cu (Alanyl-Histidyl-Lysine-Copper) was the focus of this study and showed strong follicle-stimulating and anti-apoptotic effects. GHK-Cu (Glycyl-Histidyl-Lysine-Copper) is more widely studied across dermatology and wound healing. As reviewed in the 2018 Pickart & Margolina review, both deliver copper to cells and trigger regenerative responses. Many advanced formulations use both peptides together for complementary benefits.
How does this compare to minoxidil?
The same research group at Seoul National University previously studied minoxidil using the identical DPC model (Han et al., 2004) and found similar proliferative and anti-apoptotic mechanisms. The 2018 Pickart & Margolina review noted that copper peptide hair-stimulating effects appeared comparable to 2% minoxidil. A key advantage of copper peptides is their excellent safety profile — unlike minoxidil, which commonly causes scalp irritation and dryness, copper peptides show no such side effects at effective concentrations.
Why did high concentrations of AHK-Cu inhibit hair growth?
This is called a biphasic or hormetic dose-response — common in biology. At 10⁻⁸ M, growth was inhibited by 14.8%, and at 10⁻⁷ M by 81.5%. Many growth factors show similar patterns where optimal stimulation occurs within a narrow concentration window, and excess amounts trigger inhibitory feedback. This finding is important for product formulation: effective copper peptide products need precisely calibrated concentrations, not just "more copper peptide."
Is this study considered reliable?
Yes. It was conducted at Seoul National University (one of Asia's top research institutions) with full IRB ethical approval. The methodology — combining ex vivo follicle organ culture with multiple in vitro molecular assays — is considered a strong experimental design for hair growth research. The study was published in the peer-reviewed Archives of Pharmacal Research and has been cited by numerous subsequent studies globally.
Can I apply AHK-Cu directly to my scalp?
AHK-Cu is available in topical formulations such as serums. This study showed effects at very low concentrations (picomolar to nanomolar), which is encouraging for topical application. Research suggests combining copper peptide serums with microneedling significantly enhances delivery to the dermal papilla cells. The 2025 Kuceki study demonstrated 26.5% hair regrowth with this combination approach.
How long does it take for copper peptides to show results?
In this laboratory study, measurable follicle elongation was observed within 12 days. In human clinical trials, visible results typically appear within 3–6 months of consistent use, consistent with the hair growth cycle timeline. The 2016 Lee et al. clinical trial showed significant improvements by week 16. Hair growth is a gradual process, and copper peptides work by supporting the biological foundations of each growth cycle.
Is this study only relevant for androgenetic alopecia (pattern baldness)?
The mechanisms demonstrated in this study — DPC proliferation and anti-apoptosis — are relevant to multiple types of hair loss, not just androgenetic alopecia. Any condition involving dermal papilla cell death or dysfunction could theoretically benefit from copper peptide treatment. However, most subsequent clinical research has focused on androgenetic alopecia specifically, so the strongest evidence base is for pattern hair loss.
Original Study Reference
Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human hair growth in vitro. Archives of Pharmacal Research. 2007;30(7):834–839. doi:10.1007/BF02978833. PMID: 17703734.
How to Cite This Research Summary
Hairgenetix Research Team. "Can a Copper Peptide Make Hair Follicles Grow? What This 2007 Lab Study Found." Hairgenetix Research Library, March 2026.
Available at: https://hairgenetix.com/blogs/articles/copper-peptide-ahk-cu-hair-follicle-growth-study-2007
Hairgenetix Research Library — We publish plain-language summaries of peer-reviewed clinical studies on hair growth science. Every article links directly to the original published research. Our goal is to make hair loss science accessible, transparent, and evidence-based. Browse all research summaries →
Advanced Daily Scalp Therapy for Stronger, Healthier Hair
🎯 Designed for hair loss and weak, thinning hair 🔬 Clinically Proven Ingredients 💧 Lightweight, non-greasy for easy daily use
The Hairgenetix Copper Peptide Serum is a powerful daily scalp treatment designed to stimulate hair follicles, reduce shedding, and support long-term hair health. Infused with 10% GHK-Cu and 5% AHK-Cu copper peptides, this advanced formula works at the root level to improve follicle longevity, boost collagen production, and enhance scalp circulation—creating the perfect environment for thicker, healthier hair growth.
🚀 Stimulates Hair Growth at the Follicle Level 🛡️ Reduces Hair Shedding & Strengthens Roots 🌿 Improves Scalp Health for Thicker, Healthier Hair
Advanced hair care powered by GHK-Cu copper peptides. This professional shampoo gently cleanses while supporting scalp regeneration, follicle health, and stronger hair growth. Designed to help reduce shedding, improve hair density, and create the optimal environment for healthier, thicker-looking hair with every wash.
Advanced conditioning powered by GHK-Cu copper peptides. This professional conditioner deeply nourishes the hair and scalp while supporting follicle health, strength, and resilience. Designed to reduce breakage, improve hair texture and density, and leave hair stronger, smoother, and healthier-looking with every use.
Professional GHK-Cu Complete Follicle & Scalp Activation System
🚀 Maximizes Hair Growth Support at the Follicle Level 🛡️ Reduces Shedding While Strengthening Hair from Root to Tip 🌿 Optimizes Scalp Health for Thicker, Fuller-Looking Hair
Advanced hair care powered by GHK-Cu copper peptides. This professional shampoo and conditioner set works synergistically to cleanse, nourish, and strengthen the scalp and hair while supporting follicle regeneration and long-term hair growth. Designed to help reduce shedding, improve hair density, and create the optimal environment for healthier, thicker-looking hair with consistent use.
Professional GHK-Cu Complete Follicle & Scalp Activation System
🚀 Maximizes Hair Growth Support at the Follicle Level 🛡️ Reduces Shedding While Strengthening Hair from Root to Tip 🌿 Optimizes Scalp Health for Thicker, Fuller-Looking Hair
Advanced hair care powered by GHK-Cu & AHK-Cu Copper Peptides. This professional shampoo, conditioner, and serum set works synergistically to cleanse, nourish, and activate the hair follicles at the root. The shampoo gently removes buildup and prepares the scalp, the conditioner restores moisture and resilience, and the targeted serum delivers concentrated copper peptides directly to the follicle environment. Designed to help reduce shedding, improve hair density, and create optimal conditions for healthier, thicker-looking hair with consistent use.
Can a Copper Peptide Make Hair Follicles Grow? What This 2007 Lab Study Found
Research Evidence Summary
Why This Research Matters
If you are experiencing hair loss, you have probably come across copper peptides as a potential treatment. But does the science actually support them? This 2007 study from Seoul National University is the cornerstone of copper peptide hair research — it was the first to demonstrate, using real human hair follicles, that a specific copper peptide called AHK-Cu can directly stimulate hair growth at the cellular level.
Before this study, researchers already knew that copper peptides could stimulate skin fibroblasts (the cells that produce collagen) and boost vascular endothelial growth factor (VEGF) — a molecule that improves blood supply. What they did not know was whether copper peptides could also affect the specialised cells inside hair follicles. This study answered that question with a clear yes — and mapped the specific biological pathways involved.
The findings have been cited by dozens of subsequent studies, including the 2018 Pickart & Margolina review of GHK-Cu regeneration science and the 2025 Kuceki study combining copper peptides with microneedling. This paper forms the scientific foundation for copper peptide hair treatments worldwide.
What The Researchers Did
The team at Seoul National University's Department of Dermatology took a two-pronged approach to test whether the copper peptide AHK-Cu affects hair growth:
1. Testing on real hair follicles (ex vivo organ culture)
They collected hair follicles from the occipital (back) scalp region of 10 healthy volunteers aged 20–35. A total of 240 hair follicles were isolated and placed in controlled laboratory conditions (Williams' E Medium at 37°C). Follicles were treated with AHK-Cu at concentrations ranging from 10-13 M to 10-7 M (covering six orders of magnitude), with 30 follicles per concentration group. After 12 days, the researchers measured how much each follicle had grown compared to vehicle-treated controls.
2. Testing on follicle command cells (in vitro cell culture)
They isolated dermal papilla cells (DPCs) from human hair follicles and grew them in culture dishes. These cells sit at the base of each hair follicle and act as the "command centre" that signals the hair to grow. Using the MTT assay (a standard test for cell viability), they measured whether AHK-Cu made these cells multiply faster. They also ran flow cytometry (Annexin V/PI staining) and western blot analysis to measure specific survival and death markers: Bcl-2, Bax, caspase-3, and PARP.
What Is an Ex Vivo Study?
An ex vivo study tests living tissue that has been taken from the body and maintained in laboratory conditions. Unlike a pure cell culture (where individual cells grow in a dish), ex vivo organ culture preserves the complete tissue structure — in this case, whole hair follicles with all their cell types intact. This is considered more realistic than pure in vitro testing because the natural architecture and cell-to-cell communication is maintained.
Ex vivo studies sit between test-tube experiments and full clinical trials on the evidence scale. They provide strong proof that a compound has a direct biological effect on the target tissue, but they cannot tell us how that compound will behave when applied to human skin (where absorption, distribution, and metabolism add complexity). This is why ex vivo findings need to be confirmed in human trials — which subsequent studies like the 2016 GHK peptide clinical trial and the 2021 copper tripeptide serum trial have done.
What They Found
AHK-Cu at concentrations between 10-12 and 10-9 M stimulated measurable hair follicle elongation over 12 days. The treated follicles physically grew more than the untreated controls, with the effect reaching high statistical significance. Crucially, this worked at extremely low concentrations — picomolar to nanomolar — suggesting high biological potency.
At 10-8 M, follicle elongation was inhibited by 14.8 ± 1.2% (2.3 ± 0.18 mm). At 10-7 M, inhibition reached 81.5 ± 40.8% (only 0.5 ± 0.25 mm of growth). This biphasic dose-response demonstrates that "more is not better" — there is an optimal concentration window for copper peptide efficacy.
The MTT assay confirmed that DPCs treated with AHK-Cu at 10-12 to 10-9 M proliferated at a significantly higher rate than untreated cells. More dermal papilla cells means a stronger growth signal being sent to the hair follicle. At 10-8 M, no proliferative effect was observed — consistent with the follicle results.
After 72 hours of treatment with 10-9 M AHK-Cu, the levels of cleaved caspase-3 — the "executioner" enzyme that carries out programmed cell death — were reduced by 42.7% compared to untreated controls. This is a direct measurement of reduced cell death.
PARP cleavage fragments (a downstream marker of caspase-3 activation) were reduced by 77.5% after 72 hours of treatment. This confirms the anti-apoptotic effect through a second, independent measurement. The magnitude of this reduction is particularly striking.
After 24 hours at 10-9 M, the ratio of Bcl-2 (a "stay alive" protein) to Bax (a "self-destruct" protein) shifted significantly in favour of cell survival. Bcl-2 expression increased while Bax expression decreased — both reaching statistical significance (p < 0.05 each).
How AHK-Cu Works: The Biological Mechanisms
This study identified two distinct pathways through which AHK-Cu promotes hair growth:
1. Direct proliferative effect on dermal papilla cells
AHK-Cu stimulated DPCs to multiply, increasing the pool of growth-signalling cells at the base of each follicle. Dermal papilla cells are the "command centre" of hair growth — they secrete growth factors that instruct the surrounding follicular epithelial cells to proliferate and differentiate into hair. More DPCs means a stronger, more sustained growth signal.
2. Anti-apoptotic protection of dermal papilla cells
AHK-Cu protected DPCs from programmed cell death through multiple molecular pathways:
The broader copper peptide network
The paper also notes that copper peptide complexes (including the related GHK-Cu) are known to increase VEGF (vascular endothelial growth factor) production and decrease TGF-β1 secretion by dermal fibroblasts. VEGF promotes hair growth by improving blood vessel formation around follicles, while androgen-induced TGF-β1 suppresses epithelial cell growth in androgenetic alopecia. This suggests copper peptides may work through at least four mechanisms: DPC proliferation, anti-apoptosis, VEGF stimulation, and TGF-β1 suppression.
Clinical Interpretation
Several aspects of these results deserve expert-level analysis:
How This Compares to Other Research
This foundational 2007 study has been built upon by a growing body of copper peptide research:
Experimental Parameters
Research Limitations
This study has several limitations that are important to understand in context:
What This Means For Your Hair
This study demonstrates four things that matter for anyone dealing with hair loss:
This is why copper peptides (specifically AHK-Cu and its close relative GHK-Cu) are now considered one of the most promising non-pharmaceutical approaches to hair loss. They address the root cause — follicle miniaturisation and dermal papilla cell death — rather than just masking symptoms.
Key Terms Explained
Frequently Asked Questions
Does this study prove copper peptides grow hair in real people?
This study proves that AHK-Cu directly stimulates hair follicle growth and protects the key growth cells at the cellular level, using real human tissue. However, it is a laboratory study, not a clinical trial on living patients. Subsequent human studies — including the 2016 Lee et al. clinical trial showing a 7.4× hair count increase and the 2021 Pamela R.D. placebo-controlled study — confirmed these effects in real-world use.
What is the difference between AHK-Cu and GHK-Cu?
Both are copper peptides with slightly different amino acid chains. AHK-Cu (Alanyl-Histidyl-Lysine-Copper) was the focus of this study and showed strong follicle-stimulating and anti-apoptotic effects. GHK-Cu (Glycyl-Histidyl-Lysine-Copper) is more widely studied across dermatology and wound healing. As reviewed in the 2018 Pickart & Margolina review, both deliver copper to cells and trigger regenerative responses. Many advanced formulations use both peptides together for complementary benefits.
How does this compare to minoxidil?
The same research group at Seoul National University previously studied minoxidil using the identical DPC model (Han et al., 2004) and found similar proliferative and anti-apoptotic mechanisms. The 2018 Pickart & Margolina review noted that copper peptide hair-stimulating effects appeared comparable to 2% minoxidil. A key advantage of copper peptides is their excellent safety profile — unlike minoxidil, which commonly causes scalp irritation and dryness, copper peptides show no such side effects at effective concentrations.
Why did high concentrations of AHK-Cu inhibit hair growth?
This is called a biphasic or hormetic dose-response — common in biology. At 10⁻⁸ M, growth was inhibited by 14.8%, and at 10⁻⁷ M by 81.5%. Many growth factors show similar patterns where optimal stimulation occurs within a narrow concentration window, and excess amounts trigger inhibitory feedback. This finding is important for product formulation: effective copper peptide products need precisely calibrated concentrations, not just "more copper peptide."
Is this study considered reliable?
Yes. It was conducted at Seoul National University (one of Asia's top research institutions) with full IRB ethical approval. The methodology — combining ex vivo follicle organ culture with multiple in vitro molecular assays — is considered a strong experimental design for hair growth research. The study was published in the peer-reviewed Archives of Pharmacal Research and has been cited by numerous subsequent studies globally.
Can I apply AHK-Cu directly to my scalp?
AHK-Cu is available in topical formulations such as serums. This study showed effects at very low concentrations (picomolar to nanomolar), which is encouraging for topical application. Research suggests combining copper peptide serums with microneedling significantly enhances delivery to the dermal papilla cells. The 2025 Kuceki study demonstrated 26.5% hair regrowth with this combination approach.
How long does it take for copper peptides to show results?
In this laboratory study, measurable follicle elongation was observed within 12 days. In human clinical trials, visible results typically appear within 3–6 months of consistent use, consistent with the hair growth cycle timeline. The 2016 Lee et al. clinical trial showed significant improvements by week 16. Hair growth is a gradual process, and copper peptides work by supporting the biological foundations of each growth cycle.
Is this study only relevant for androgenetic alopecia (pattern baldness)?
The mechanisms demonstrated in this study — DPC proliferation and anti-apoptosis — are relevant to multiple types of hair loss, not just androgenetic alopecia. Any condition involving dermal papilla cell death or dysfunction could theoretically benefit from copper peptide treatment. However, most subsequent clinical research has focused on androgenetic alopecia specifically, so the strongest evidence base is for pattern hair loss.
How to Cite This Research Summary
Hairgenetix Research Team. "Can a Copper Peptide Make Hair Follicles Grow? What This 2007 Lab Study Found." Hairgenetix Research Library, March 2026.
Available at: https://hairgenetix.com/blogs/articles/copper-peptide-ahk-cu-hair-follicle-growth-study-2007
Related Research on Hairgenetix